Drugs / ABBV-706
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05599984 | Dec 2022 → Nov 2027 expected | cancer | AbbVie | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07155174 | Nov 2025 → Apr 2029 expected | small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07365241 | Jul 2026 → Sep 2030 expected | small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT07310277 Background | — | small cell lung carcinoma | AbbVie | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-08-21 | AbbVie | Results AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline abbvie.com ↗
New safety analyses from 240 patients who received ABBV-706 monotherapy showed generally manageable hematologic and gastrointestinal toxicities, with the |
| 2026-05-21 | AbbVie | Results AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline abbvie.com ↗
The safety profile was comparable with previously reported data. |
| 2025-10-13 | AbbVie | Results AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors abbvie.com ↗
Patients with 100% ctDNA clearance had significantly higher PFS and overall survival (OS) vs. patients without ctDNA clearance. |
| 2024-05-28 | AbbVie | Results AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform abbvie.com ↗
The data demonstrate that among a total of 48 efficacy-evaluable patients (23 SCLC and 25 NEN), the overall confirmed objective response rate was 43.8%. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-706 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07155174 ↗ |
| Modality | Other / unclassified | “ABBV-706, an antibody-drug conjugate with a SEZ6-directed antibody linked to topoisomerase-1 inhibitor (Top1i)” PMID 42225988 ↗ Jun 2026 |
| Route | Intravenous | “was administered intravenously every 3 weeks (Q3W)” PMID 42225988 ↗ Jun 2026 |
| Target | SEZ6 | “ABBV-706, an antibody-drug conjugate with a SEZ6-directed antibody linked to topoisomerase-1 inhibitor (Top1i)” PMID 42225988 ↗ Jun 2026 |